GlassScriptPhysician profile
Brandy M Gettys
NPI 1447781158
$3,975.86
in general payments reported to CMS, 2019-2025
27 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.70 · 2020: $209 · 2021: $722 · 2022: $1,035 · 2023: $1,151 · 2024: $471 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.43 | 2021-2024 | |
| Novo Nordisk INC | $614.87 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $422.86 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $367.18 | 2020-2024 | Breztri, Airsupra |
| Lilly USA, LLC | $359.31 | 2019-2023 | Mounjaro, Jardiance |
| Pfizer INC. | $332.92 | 2019-2023 | |
| Abbott Laboratories | $274.58 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $144.35 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.50 | 2021-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.08 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $88.79 | 2020-2022 | |
| Glaxosmithkline, LLC. | $88.41 | 2019-2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $78.85 | 2020-2022 | |
| Corium, LLC | $73.27 | 2022-2023 | Adlarity |
| Axsome Therapeutics, INC. | $57.69 | 2023 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $27.34 | 2022 | |
| Cranial Technologies, INC | $18.96 | 2020 | |
| Xeris Pharmaceuticals, INC. | $18.01 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $16.93 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $16.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.23 | 2023 | Spravato |
| Amgen INC. | $13.17 | 2022 | |
| Genentech USA, INC. | $13.06 | 2020 | |
| Renalytix Ai, INC. | $12.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.79 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Gettys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.